These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
500 related articles for article (PubMed ID: 25727748)
1. Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation. Ferreira J; Mirco A Rev Port Cardiol; 2015 Mar; 34(3):179-91. PubMed ID: 25727748 [TBL] [Abstract][Full Text] [Related]
2. [Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain]. Monreal-Bosch M; Soulard S; Crespo C; Brand S; Kansal A Rev Neurol; 2017 Mar; 64(6):247-256. PubMed ID: 28272725 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting. Athanasakis K; Karampli E; Tsounis D; Bilitou A; Kyriopoulos J Clin Drug Investig; 2015 Nov; 35(11):693-705. PubMed ID: 26385756 [TBL] [Abstract][Full Text] [Related]
4. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. Rudakova AV; Tatarskiĭ BA Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243 [No Abstract] [Full Text] [Related]
7. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis. Escobar C; Martí-Almor J; Pérez Cabeza A; Martínez-Zapata MJ Rev Esp Cardiol (Engl Ed); 2019 Apr; 72(4):305-316. PubMed ID: 29606361 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal. Costa J; Fiorentino F; Caldeira D; Inês M; Lopes Pereira C; Pinheiro L; Vaz-Carneiro A; Borges M; Gouveia M Rev Port Cardiol; 2015 Dec; 34(12):723-37. PubMed ID: 26616542 [TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. Verhoef TI; Redekop WK; Hasrat F; de Boer A; Maitland-van der Zee AH Am J Cardiovasc Drugs; 2014 Dec; 14(6):451-62. PubMed ID: 25326294 [TBL] [Abstract][Full Text] [Related]
10. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Hernandez I; Smith KJ; Zhang Y Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008 [TBL] [Abstract][Full Text] [Related]
12. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. Hospodar AR; Smith KJ; Zhang Y; Hernandez I Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750 [TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan. Liu CY; Chen HC Clin Drug Investig; 2017 Mar; 37(3):285-293. PubMed ID: 27988835 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283 [TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Shah A; Shewale A; Hayes CJ; Martin BC Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation. Hernandez I; Zhang Y; Saba S Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318 [TBL] [Abstract][Full Text] [Related]
17. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Lip GY; Larsen TB; Skjøth F; Rasmussen LH J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324 [TBL] [Abstract][Full Text] [Related]
18. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]